Co-occurring genetic alterations in the plasma of patients, including WNT/b-catenin and cell-cycle-gene alterations, limited EGFR TKI response in EGFR mutant NSCLC (34). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.